目的评估超声乳化白内障摘出人工晶状体植入术(PEI)联合房角分离术(GSL)及房角切开术(GT)治疗中晚期原发性闭角型青光眼(PACG)的有效性和安全性。
方法采用系列病例观察性研究方法，于2020年8月至2021年6月在中山大学中山眼科中心连续纳入中晚期PACG患者50例50眼，所有患眼均接受PEI+GSL+GT，随访时间至少6个月，平均随访7.5(6，10)个月。采用Goldmann压平眼压计测定患者手术前后眼压；采用ETDRS视力表测定患眼最佳矫正视力(BCVA)，并转换为LogMAR视力分析；收集抗青光眼用药种类及数量信息和手术并发症资料。计算患眼手术成功率，完全成功定义为术后不使用任何抗青光眼药物眼压为5~18 mmHg(1 mmHg＝0.133 kPa)且眼压较基线下降20%，无威胁视力的并发症，无需接受额外的抗青光眼手术，无光感丢失；条件成功定义为使用或不使用抗青光眼药物达到上述条件。
结果术眼术前平均眼压为(28.81±7.81)mmHg，末次随访平均眼压为(13.41±4.10)mmHg，术后眼压较术前显著下降，差异有统计学意义( t＝12.260， P<0.001)；与术前比较，术后眼压平均降低13.80(9.10，19.40)mmHg，降幅为51.1%(38.6%，67.1%)。术前平均BCVA为(0.92±0.11)LogMAR，术后末次随访时为(0.88±0.10)LogMAR，手术前后BCVA比较差异无统计学意义( t＝-0.560， P＝0.580)。术前平均使用降眼压药物2(1，3)种，术后为0(0，0)种。手术完全成功率为80%(40/50)，条件成功率为94%(47/50)。术中和术后并发症主要包括前房积血7眼，一过性眼压升高7眼，角膜水肿3眼，未出现威胁视力的并发症。
结论PEI+GSL+GT治疗中晚期PACG能够有效降低眼压、减少降眼压药物的使用种类和数量，手术安全性好。
ObjectiveTo evaluate the effectiveness and safety of phacoemulsification cataract extraction combined with intraocular lens implantation (PEI) plus goniosynechilysis (GSL) and goniotomy (GT) for advanced primary angle-closure glaucoma (PACG).
MethodsAn observational case series study was performed.Fifty eyes of 50 patients with advanced PACG were enrolled in Zhongshan Ophthalmic Center from August 2020 to June 2021.All the patients received PEI+ GSL+ GT and were followed up for over 6 months, with a mean follow-up of 7.5 (6, 10) months.Intraocular pressure (IOP) was measured with a Goldmann applanation tonometer.Best corrected visual acuity (BCVA) was examined with an ETDRS chart and converted to logarithm of the minimum angle of resolution (LogMAR) units for analysis.Types and number of anti-glaucoma medications applied before and after surgery, and the surgical complications were collected.Success rate of surgery was calculated.Complete surgical success was defined as an IOP of 5-18 mmHg (1 mmHg=0.133 kPa) with a reduction of 20% from baseline without anti-glaucoma medication, no vision-threatening complications, no loss of light perception, and no reoperation.Qualified success was defined as an IOP of 5-18 mmHg with a reduction of 20% from baseline with or without anti-glaucoma medication, no vision-threatening complications, no loss of light perception, and no reoperation.This study adhered to the Declaration of Helsinki.This research protocol was approved by an Ethics Committee of Zhongshan Ophthalmic Center (No.2021KYPJ177). Written informed consent was obtained from each subject before entering the cohort.
ResultsThe mean preoperative IOP was (28.81±7.81)mmHg, and the IOP at the end of follow-up was (13.41±4.10)mmHg, showing a statistically significant decrease ( t=12.260, P<0.001). The postoperative IOP was decreased by 13.80 (9.10, 19.40)mmHg, with a percentage decrease of 51.1% (38.6%, 67.1%). The mean preoperative and postoperative BCVA was (0.92±0.11) LogMAR and (0.88±0.10) LogMAR, respectively, and no significant difference was found ( t=-0.560, P=0.580). The number of anti-glaucoma medications was reduced from 2 (1, 3) before operation to 0 (0, 0) after operation.The complete success rate of surgery was 80% (40/50), and the qualified success rate was 94% (47/50). Surgical complications mainly included hyphema in 7 eyes, IOP spike in 7 eyes, and corneal edema in 3 eyes.No vision-threatening complication occurred.
ConclusionsPEI+ GSL+ GT is preliminarily effective and safe for advanced PACG by reducing IOP and application of anti-glaucoma medications with few complications.
宋云河,张英哲,林凤彬,等. PEI联合房角分离术及房角切开术治疗中晚期PACG疗效及安全性评估[J]. 中华实验眼科杂志,2022,40(04)：334-339.
DOI:10.3760/cma.j.cn115989-20211215-00692版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
张秀兰：参与研究选题、研究设计、研究实施、数据收集整理和分析、论文智力性内容修改和定稿；宋云河：参与研究资料整理、数据收集及分析、论文撰写及修改；林凤彬、张英哲、梁小红、魏孟欢、陈姝宇：参与患者随访、研究指标测量、数据整理和分析、论文修改；聂昕、施继光、陈太峰：进修医师，参与患者观察、研究数据提取整理；王贞玉：参与研究数据提取和统计学分析、论文修改
文档即答
智问智答
机器翻译
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
